Evidence map›Paper›PMID 34303747›Full record

ArticleAntiviral research2021

Prophylactic treatment with BX795 blocks activation of AKT and its downstream targets to protect vaginal keratinocytes and vaginal epithelium from HSV-2 infection.

Krishnaraju Madavaraju, Tejabhiram Yadavalli, Sudhanshu Kumar Singh, Farreh Qatanani, Deepak Shukla

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antiviral research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Krishnaraju MadavarajuDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA.
Tejabhiram YadavalliDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA.
Sudhanshu Kumar SinghDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA; Department of Bioengineering, University of Illinois at Chicago, Chicago, IL, 60607, USA.
Farreh QatananiDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA.
Deepak ShuklaDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA; Department of Bioengineering, University of Illinois at Chicago, Chicago, IL, 60607, USA; Department of Microbiology and Immunology, University of Illinois at Chicago, Chicago, IL, 60612, USA. Electronic address: dshukla@uic.edu.
University of Illinois Chicago · US

Funding

A small molecule inhibitor of HSV genital infectionsR01AI139768 · NIAID · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SHUKLA, DEEPAK · 2018 to 2021
$1.6M
NIAID NIH HHS R01 AI139768
6 · The paper itself

Abstract

Genital herpes infections in humans are usually caused by herpes simplex virus type-2 (HSV-2), which result in recurrent lesions in the anogenital region. Past studies have shown that a viral protein translation inhibitor, BX795 is capable of mitigating HSV-2 infection both in vitro and in vivo when dosed therapeutically. However, any preventative benefits of this compound against HSV-2 infection remain poorly understood. In this study, we show that BX795 when added prophylactically to human vaginal keratinocytes generates strong preventative effects against a future HSV-2 infection. As a possible mechanism for this action, we found that BX795 efficiently reduces phosphorylation of AKT and its downstream targets p70S6K and 4EBP1. Our in-silico protein docking studies support our immunoblotting results and provide further credence to the proposed mechanism. Using a murine model of vaginal infection, we show that prior treatment with BX795 is also protective in vivo and leads to lower viral replication in the vaginal tissue.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsAntiviral AgentsCell Cycle ProteinsFemaleHerpes GenitalisKeratinocytesMetabolic Networks and PathwaysMiceMice, Inbred BALB COncogene Protein v-aktPyrimidinesRibosomal Protein S6 Kinases, 70-kDaThiophenesVaginaVirus ReplicationAdaptor Proteins, Signal TransducingAntiviral AgentsBX795Cell Cycle ProteinsEif4ebp1 protein, mouseOncogene Protein v-aktPyrimidinesRibosomal Protein S6 Kinases, 70-kDaThiophenes4EBP1AKTBX795HSV-2p70S6KProphylaxis

Identifiers

PMID34303747
PMCPMC8446323
OpenAlexW3185406344

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.